194 related articles for article (PubMed ID: 27143662)
1. Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial.
Arenas-Pinto A; Stöhr W; Jäger HR; Haddow L; Clarke A; Johnson M; Chen F; Winston A; Godi C; Thust S; Trombin R; Cairns J; Solanky BS; Golay X; Paton NI;
Clin Infect Dis; 2016 Jul; 63(2):257-64. PubMed ID: 27143662
[TBL] [Abstract][Full Text] [Related]
2. The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection.
Paton NI; Stöhr W; Oddershede L; Arenas-Pinto A; Walker S; Sculpher M; Dunn DT
Health Technol Assess; 2016 Mar; 20(21):1-158. PubMed ID: 26986803
[TBL] [Abstract][Full Text] [Related]
3. Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy.
Pérez-Valero I; González-Baeza A; Estébanez M; Montes-Ramírez ML; Bayón C; Pulido F; Bernardino JI; Zamora FX; Monge S; Gaya F; Lagarde M; Rubio R; Hernando A; Arnalich F; Arribas JR
PLoS One; 2013; 8(7):e69493. PubMed ID: 23936029
[TBL] [Abstract][Full Text] [Related]
4. Genital secretion HIV RNA shedding in HIV-positive patients on ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional sub-study from the PIVOT Trial.
Arenas-Pinto A; Stöhr W; Khoo S; Clarke A; Beeching N; Warwick Z; Lee V; Else L; Wiggins R; Ferns B; Nastouli E; Dunn D; Lacey CJ; Paton NI;
Antivir Ther; 2020; 25(1):55-59. PubMed ID: 32202510
[TBL] [Abstract][Full Text] [Related]
5. Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial.
Paton NI; Stöhr W; Arenas-Pinto A; Fisher M; Williams I; Johnson M; Orkin C; Chen F; Lee V; Winston A; Gompels M; Fox J; Scott K; Dunn DT;
Lancet HIV; 2015 Oct; 2(10):e417-26. PubMed ID: 26423649
[TBL] [Abstract][Full Text] [Related]
6. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
7. Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals.
Negredo E; Estrada V; Domingo P; Gutiérrez MD; Mateo GM; Puig J; Bonjoch A; Ornelas A; Echeverría P; Estany C; Toro J; Clotet B
J Antimicrob Chemother; 2017 Mar; 72(3):844-849. PubMed ID: 27999056
[TBL] [Abstract][Full Text] [Related]
8. Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.
Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Sierra Madero J; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Fisher M; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Arnaiz JA; Cooper D; Rockstroh JK; Mallon P; Emery S;
Clin Infect Dis; 2016 Jul; 63(1):122-32. PubMed ID: 27048747
[TBL] [Abstract][Full Text] [Related]
9. Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial.
Bunupuradah T; Kiertiburanakul S; Avihingsanon A; Chetchotisakd P; Techapornroong M; Leerattanapetch N; Kantipong P; Bowonwatanuwong C; Banchongkit S; Klinbuayaem V; Mekviwattanawong S; Nimitvilai S; Jirajariyavej S; Prasithsirikul W; Munsakul W; Bhakeecheep S; Chaivooth S; Phanuphak P; Cooper DA; Apornpong T; Kerr SJ; Emery S; Ruxrungtham K;
Lancet HIV; 2016 Aug; 3(8):e343-e350. PubMed ID: 27470026
[TBL] [Abstract][Full Text] [Related]
10. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
[TBL] [Abstract][Full Text] [Related]
11. Brain Perfusion, Regional Volumes, and Cognitive Function in Human Immunodeficiency Virus-positive Patients Treated With Protease Inhibitor Monotherapy.
Haddow LJ; Godi C; Sokolska M; Cardoso MJ; Oliver R; Winston A; Stöhr W; Clarke A; Chen F; Williams IG; Johnson M; Paton N; Arenas-Pinto A; Golay X; Jäger HR
Clin Infect Dis; 2019 Mar; 68(6):1031-1040. PubMed ID: 30084882
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials.
Arribas JR; Girard PM; Paton N; Winston A; Marcelin AG; Elbirt D; Hill A; Hadacek MB
HIV Med; 2016 May; 17(5):358-67. PubMed ID: 26709605
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
14. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial.
Arribas JR; Pialoux G; Gathe J; Di Perri G; Reynes J; Tebas P; Nguyen T; Ebrahimi R; White K; Piontkowsky D
Lancet Infect Dis; 2014 Jul; 14(7):581-9. PubMed ID: 24908551
[TBL] [Abstract][Full Text] [Related]
15. Ritonavir-boosted lopinavir as maintenance monotherapy in HIV-infected patients who achieved viral suppression during a second-line protease inhibitor-based regimen: a pilot randomized trial (BIDI-MONO).
Siripassorn K; Chottanapund S; Prasithsirikul W; Manosuthi W
J Int Assoc Provid AIDS Care; 2014; 13(4):353-60. PubMed ID: 25513033
[TBL] [Abstract][Full Text] [Related]
16. Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial.
Oddershede L; Walker S; Stöhr W; Dunn DT; Arenas-Pinto A; Paton NI; Sculpher M;
Pharmacoeconomics; 2016 Aug; 34(8):795-804. PubMed ID: 26966125
[TBL] [Abstract][Full Text] [Related]
17. Potential for simplification of HIV treatment with boosted protease inhibitor monotherapy.
Reina E; San Miguel R; Larrea N; Garcia P; Napal V
Int J Clin Pharm; 2012 Dec; 34(6):911-6. PubMed ID: 23007692
[TBL] [Abstract][Full Text] [Related]
18. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
[TBL] [Abstract][Full Text] [Related]
19. Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.
Galli L; Spagnuolo V; Bigoloni A; D'Arminio Monforte A; Montella F; Antinori A; Di Biagio A; Rusconi S; Guaraldi G; Di Giambenedetto S; Borderi M; Gibellini D; Caramatti G; Lazzarin A; Castagna A;
J Antimicrob Chemother; 2016 Jun; 71(6):1637-42. PubMed ID: 26945711
[TBL] [Abstract][Full Text] [Related]
20. Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 substudy.
Valantin MA; Kolta S; Flandre P; Algarte Genin M; Meynard JL; Ponscarme D; Slama L; Cuzin L; de Kerviler E; Inaoui R; Katlama C
HIV Med; 2012 Sep; 13(8):505-15. PubMed ID: 22416798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
